Fully Automated Hepatitis E Virus Assay Now CE-marked
By LabMedica International staff writers Posted on 06 Aug 2014 |
Image: The Procleix Panther System is a highly evolved, fully integrated and automated NAT (nucleic acid technology) system for blood and plasma screening (Photo courtesy of Grifols Diagnostic Solutions Inc.).
Clinical laboratories in Europe now have available a fully automated and highly sensitive NAT (nucleic acid technology) test with CE-marking for the detection of Hepatitis E virus (HEV) RNA in donors of blood, blood components, tissues, and organs.
The Procleix HEV assay is produced by Grifols Diagnostic Solutions Inc. (Barcelona, Spain) and was designed for use on the fully automated Procleix Panther analytical system, which is manufactured by Hologic Inc. (Bedford, MA, USA) and distributed by Grifols.
The assay employs nucleic acid amplification to detect all four genotypes of the hepatitis E virus in plasma and serum specimens from human donors, tested individually or in pools. It is also intended for use in testing plasma and serum to screen organ and tissue donors, including cadaveric (non-heart-beating) donors.
The assay will be sold in the European Union for use on the Procleix Panther system, which performs nucleic acid extraction, amplification, and detection all in a single tube. The Procleix Panther system, which was launched in 2012, features built-in process controls for sample and results integrity, and boasts full sample traceability with positive sample ID tracking and RFID tagged fluids. The instrumentation provides precise pipetting with liquid level sensors and dispensers that facilitate consistency and accuracy of system results.
“As the leading provider of NAT solutions to support safe transfusions and efficient, high-quality testing, we are proud to have accelerated development of this test—already scheduled for use in Japan—to meet the needs of the blood community,” said Carsten Schroeder, president of Grifols Diagnostic Solutions Incorporated.
Related Links:
Grifols Diagnostic Solutions Inc.
Hologic, Inc.
The Procleix HEV assay is produced by Grifols Diagnostic Solutions Inc. (Barcelona, Spain) and was designed for use on the fully automated Procleix Panther analytical system, which is manufactured by Hologic Inc. (Bedford, MA, USA) and distributed by Grifols.
The assay employs nucleic acid amplification to detect all four genotypes of the hepatitis E virus in plasma and serum specimens from human donors, tested individually or in pools. It is also intended for use in testing plasma and serum to screen organ and tissue donors, including cadaveric (non-heart-beating) donors.
The assay will be sold in the European Union for use on the Procleix Panther system, which performs nucleic acid extraction, amplification, and detection all in a single tube. The Procleix Panther system, which was launched in 2012, features built-in process controls for sample and results integrity, and boasts full sample traceability with positive sample ID tracking and RFID tagged fluids. The instrumentation provides precise pipetting with liquid level sensors and dispensers that facilitate consistency and accuracy of system results.
“As the leading provider of NAT solutions to support safe transfusions and efficient, high-quality testing, we are proud to have accelerated development of this test—already scheduled for use in Japan—to meet the needs of the blood community,” said Carsten Schroeder, president of Grifols Diagnostic Solutions Incorporated.
Related Links:
Grifols Diagnostic Solutions Inc.
Hologic, Inc.
Latest Microbiology News
- Integrated Solution Ushers New Era of Automated Tuberculosis Testing
- Automated Sepsis Test System Enables Rapid Diagnosis for Patients with Severe Bloodstream Infections
- Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases
- Clinical Decision Support Software a Game-Changer in Antimicrobial Resistance Battle
- New CE-Marked Hepatitis Assays to Help Diagnose Infections Earlier
- 1 Hour, Direct-From-Blood Multiplex PCR Test Identifies 95% of Sepsis-Causing Pathogens
- Mouth Bacteria Test Could Predict Colon Cancer Progression
- Unique Metabolic Signature Could Enable Sepsis Diagnosis within One Hour of Blood Collection
- Groundbreaking Diagnostic Platform Provides AST Results With Unprecedented Speed
- Simple Blood Test Combined With Personalized Risk Model Improves Sepsis Diagnosis
- Blood Analysis Predicts Sepsis and Organ Failure in Children
- TB Blood Test Could Detect Millions of Silent Spreaders
- New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours
- New Tuberculosis Test to Expand Testing Access in Low- and Middle-Income Countries
- Rapid Test Diagnoses Tropical Disease within Hours for Faster Antibiotics Treatment
- Rapid Molecular Testing Enables Faster, More Targeted Antibiotic Treatment for Pneumonia